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Background
In 2010 we reported prevention of acquisition of a
repeated SIVE660 challenge in rhesus macaques vacci-
nated with a SIV239 DNA/MVA vaccine that co-
expressed GM-CSF and VLP in the DNA prime. The
reduced risk of infection correlated with the avidity of
Env-specific IgG. Here we report studies on the longev-
ity and breadth of this protective response.
Methods
Following the initial 12 challenges, 5 uninfected rhesus
were monitored for one year, boosted with 1x108 pfu of
MVA/SIV239, and re-challenged 6 months later with 12
weekly rectal doses of SIVE660. The resulting four unin-
fected macaques were held an additional 6 months and
challenged with 12 weekly rectal doses of SIV251. Avid-
ity of Env-specific IgG was determined using a NaSCN
elution ELISA. Per exposure efficacy was estimated
using a leaky effects model.
Results
Per exposure efficacies were 90% and 94% for the 1st
and 2nd SIVE660 series, respectively, and 72% for the
SIV251 series of challenges. For the SIVE660 series, 50%
infection was reached by the 3rd challenge for controls,
but never reached in vaccinated animals. For the SIV251
series, 50% infection was reached by the 2nd challenge
for controls but not until 10 challenges for vaccinated
animals. Both SIVE660 and SIV251 series showed transi-
ent low “blips” of virus. None of five E660 “blips”
resulted in anamnestic systemic Ab, whereas two of
three SIV251 blips resulted in such. Correlates also dif-
fered for the two infections with the avidity of Env-spe-
cific IgG correlating with prevention of acquisition for
SIVE660 but not SIV251.
Conclusion
A DNA/MVA vaccine in which GM-CSF is co-
expressed in the DNA prime can provide substantial
prevention of acquisition against serial challenges over a
three year period of time. Our results also reveal
SIVE660 and SIV251 rectal challenges differing in their
ability to initiate systemic Ab responses and in their cor-
relate for prevention of acquisition.
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